12 Month Price Forecast For HOLX
Distance to HOLX Price Forecasts
HOLX Price Momentum
๐ค Considering Hologic (HOLX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 3:27 AM UTC
HOLX Analyst Ratings & Price Targets
Based on our analysis of 27 Wall Street analysts, HOLX has a neutral consensus with a median price target of $80.00 (ranging from $70.00 to $95.00). The overall analyst rating is Buy (7.0/10). Currently trading at $63.24, the median forecast implies a 26.5% upside. This outlook is supported by 7 Buy, 14 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Andrew Cooper at Raymond James, projecting a 50.2% upside. Conversely, the most conservative target is provided by Vijay Kumar at Evercore ISI Group, suggesting a 10.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HOLX Analyst Consensus
HOLX Price Target Range
Latest HOLX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HOLX.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 6, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $84.00 |
Feb 6, 2025 | Raymond James | Andrew Cooper | Outperform | Reiterates | $90.00 |
Feb 6, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
Feb 6, 2025 | Leerink Partners | Puneet Souda | Market Perform | Downgrade | $75.00 |
Feb 6, 2025 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $73.00 |
Feb 6, 2025 | RBC Capital | Conor McNamara | Sector Perform | Maintains | $85.00 |
Feb 3, 2025 | Needham | Mike Matson | Hold | Downgrade | $90.00 |
Jan 13, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $82.00 |
Jan 13, 2025 | Needham | Mike Matson | Buy | Reiterates | $90.00 |
Dec 19, 2024 | Needham | Mike Matson | Buy | Reiterates | $90.00 |
Dec 13, 2024 | Wolfe Research | Doug Schenkel | Peer Perform | Initiates | $0.00 |
Dec 10, 2024 | Jefferies | Tycho Peterson | Hold | Initiates | $85.00 |
Nov 5, 2024 | JP Morgan | Casey Woodring | Overweight | Maintains | $94.00 |
Nov 5, 2024 | Mizuho | Anthony Petrone | Outperform | Maintains | $87.00 |
Nov 5, 2024 | Raymond James | Andrew Cooper | Outperform | Maintains | $95.00 |
Nov 5, 2024 | UBS | Elizabeth Garcia | Neutral | Maintains | $90.00 |
Nov 5, 2024 | RBC Capital | Conor McNamara | Sector Perform | Maintains | $89.00 |
Oct 15, 2024 | Needham | Mike Matson | Buy | Reiterates | $90.00 |
Oct 8, 2024 | Leerink Partners | Puneet Souda | Outperform | Maintains | $90.00 |
Oct 4, 2024 | Mizuho | Anthony Petrone | Outperform | Maintains | $90.00 |
Stocks Similar to Hologic Inc
The following stocks are similar to Hologic based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Hologic Inc (HOLX) Financial Data
Hologic Inc has a market capitalization of $14.26B with a P/E ratio of 20.1x. The company generates $3.99B in trailing twelve-month revenue with a 17.6% profit margin.
Revenue growth is +4.5% quarter-over-quarter, while maintaining an operating margin of +24.4% and return on equity of +13.8%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Hologic Inc (HOLX) Company Overview
About Hologic Inc
Develops diagnostic and surgical products for women's health.
Hologic, Inc. generates revenue through the development, manufacturing, and supply of a diverse range of medical products focused on women's health. The company operates across four segmentsโDiagnostics, Breast Health, GYN Surgical, and Skeletal Healthโoffering solutions such as molecular diagnostic assays, breast cancer care technologies, and surgical systems. Their products are sold through direct sales, independent distributors, and sales representatives, ensuring a broad market reach.
Founded in 1985 and based in Marlborough, Massachusetts, Hologic, Inc. is committed to early detection and treatment in women's health care. The company offers innovative solutions, including advanced imaging systems and minimally invasive surgical products, positioning itself as a key player in the healthcare industry.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
6,990
CEO
Mr. Stephen P. MacMillan
Country
United States
IPO Year
1990
Website
www.hologic.comHologic Inc (HOLX) Latest News & Analysis
Hologic (HOLX) is currently a highly monitored stock by Zacks.com users, indicating increased investor interest and potential future developments to watch.
Increased attention from Zacks.com users suggests heightened investor interest in Hologic (HOLX), potentially impacting its stock performance and market sentiment.
Hologic's overseas revenue trends are impacting Wall Street forecasts and the stock's future outlook. Investors should monitor these developments for potential effects on performance.
Hologic's overseas revenue trends can directly influence earnings forecasts and stock valuation, impacting investment decisions and market sentiment regarding future growth.
Hologic's strong performance in molecular diagnostics boosts investor optimism, but a weak macroeconomic outlook poses potential concerns.
Hologic's strong molecular diagnostics performance boosts confidence, while economic headwinds may impact overall growth, affecting investment decisions and market sentiment.
Hologic's Surgical business is experiencing strong growth by expanding its technologies into new global markets.
Hologic's Surgical business growth signals increased revenue potential and market expansion, which may enhance overall company valuation and attract investment interest.
Hologic reduced its fiscal 2025 revenue forecast due to declining breast health product sales, resulting in a 5% drop in share price after the announcement.
Hologic's lowered revenue forecast indicates declining demand, negatively impacting future earnings and investor sentiment, leading to a 5% drop in share price.
Hologic, Inc. (NASDAQ: HOLX) will hold its Q1 2025 Earnings Conference Call on February 5, 2025, at 4:30 PM ET, featuring key executives and analysts from various firms.
Hologic's Q1 2025 earnings call indicates upcoming financial performance insights, which can influence stock valuations and investor sentiment.
Frequently Asked Questions About HOLX Stock
What is Hologic Inc's (HOLX) stock forecast for 2025?
Based on our analysis of 27 Wall Street analysts, Hologic Inc (HOLX) has a median price target of $80.00. The highest price target is $95.00 and the lowest is $70.00.
Is HOLX stock a good investment in 2025?
According to current analyst ratings, HOLX has 7 Buy ratings, 14 Hold ratings, and 0 Sell ratings. The stock is currently trading at $63.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for HOLX stock?
Wall Street analysts predict HOLX stock could reach $80.00 in the next 12 months. This represents a 26.5% increase from the current price of $63.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Hologic Inc's business model?
Hologic, Inc. generates revenue through the development, manufacturing, and supply of a diverse range of medical products focused on women's health. The company operates across four segmentsโDiagnostics, Breast Health, GYN Surgical, and Skeletal Healthโoffering solutions such as molecular diagnostic assays, breast cancer care technologies, and surgical systems. Their products are sold through direct sales, independent distributors, and sales representatives, ensuring a broad market reach.
What is the highest forecasted price for HOLX Hologic Inc?
The highest price target for HOLX is $95.00 from Andrew Cooper at Raymond James, which represents a 50.2% increase from the current price of $63.24.
What is the lowest forecasted price for HOLX Hologic Inc?
The lowest price target for HOLX is $70.00 from Vijay Kumar at Evercore ISI Group, which represents a 10.7% increase from the current price of $63.24.
What is the overall HOLX consensus from analysts for Hologic Inc?
The overall analyst consensus for HOLX is neutral. Out of 27 Wall Street analysts, 7 rate it as Buy, 14 as Hold, and 0 as Sell, with a median price target of $80.00.
How accurate are HOLX stock price projections?
Stock price projections, including those for Hologic Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.